PRM55 - Comparison of the Prices Used in the Manufacturers’ Budget Impact Analyses and the Prices from Reimbursed Drugs List

Abstract

To compare official prices and refunding limits of the selected drugs with the prices and limits used in the manufacturers’ Budget Impact Analyses (BIAs) submitted in the reimbursement applications and in the manufacturers’ documentations from request for removing, altering the level or method of financing of medicines to AHTAPol and to verify the accuracy of their assumptions. Prices and limits proposed in BIAs in years 2007-2011 and official prices and limits for the same medicine were compared. Only BIAs for medicines which had been reimbursed for at least one year were included in the analysis. The official prices and limits were obtained from reimbursed drugs list published in Ministry of Health’s Orders. In the studied period, 72 drugs were included in the analysis. Among them, 51,39% (37/72) were from reimbursement applications and 48,61% (35/72) were from requests for removing, altering the level or method of financing of medicines, respectively. As a result, 13% (9/72) of the prices proposed in the BIAs were underestimated. Median and mean difference (MD) between official prices and prices used in BIAs for the same medicine were 95% and 91% respectively. The overestimation was found in 39% BIAs (28/72); median = 117%, MD = 124%. Rest of the prices were equal 49% (35/72). Limits were underestimated in 8% (6/72) of the BIAs. Median and mean difference between official prices and prices used in BIAs were 97% and 98% respectively. Overestimation of the limits was found in 57% (41/72) of the BIAs; median = 133%, MD = 117%. Rest of the limits were equal 35% (25/72). Among the contradictory prices and limits official ones were higher than the prices assumed in BIAs for the same medicines. There is a strong need for further research.